Associated Papers
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Eadon MT et al.
Clinical Pharmacology and Therapeutics, 2025
Residue Variations in Human N‑Acetyltransferase 2 Enzyme Alleles: From Rapid to Slow Acetylation.
Veldman W et al.
Acs Omega, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
Hein DW et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
Yuliwulandari R et al.
Journal of Human Genetics, 2016
Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.
Sim E et al.
British Journal of Pharmacology, 2014
Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T et al.
Gene, 2014
Structural and biochemical characterization of an active arylamine N-acetyltransferase possessing a non-canonical Cys-His-Glu catalytic triad.
Kubiak X et al.
The Journal of Biological Chemistry, 2013
Full-gene-sequencing analysis of N-acetyltransferase-2 in an adult Indian population.
Tilak AV et al.
Genetic Testing and Molecular Biomarkers, 2013
Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity.
Kubiak X et al.
Expert Opinion on Drug Metabolism & Toxicology, 2013
Arylamine N-acetyltransferase 2 genotypes in a Mexican population.
Taja-Chayeb L et al.
Genetics and Molecular Research : Gmr, 2012
Effects of single nucleotide polymorphisms on human N-acetyltransferase 2 structure and dynamics by molecular dynamics simulation.
Rajasekaran M et al.
Plos One, 2011
Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure.
Teixeira RL et al.
Mutation Research, 2010
Probing the catalytic potential of the hamster arylamine N-acetyltransferase 2 catalytic triad by site-directed mutagenesis of the proximal conserved residue, Tyr190.
Zhou X et al.
The Febs Journal, 2009
Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups.
Kang TS et al.
Journal of Clinical Pharmacy and Therapeutics, 2009
N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.
Hein DW
Expert Opinion on Drug Metabolism & Toxicology, 2009
Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews, 2009
Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.
Walraven JM et al.
Current Drug Metabolism, 2008
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
Arylamine N-acetyltransferases: from structure to function.
Sim E et al.
Drug Metabolism Reviews, 2008
Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.
Wu H et al.
The Journal of Biological Chemistry, 2007
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2.
Zang Y et al.
Carcinogenesis, 2007
Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2.
Zang Y et al.
Pharmacogenetics and Genomics, 2007
[Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
Goldenkova-Pavlova IV et al.
Genetika, 2006
Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects.
Straka RJ et al.
Journal of Clinical Pharmacology, 2006
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene, 2006
Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population.
Rabstein S et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2006
Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines.
Sandy J et al.
The Biochemical Journal, 2005
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
TaqMan real time-polymerase chain reaction methods for determination of nucleotide polymorphisms in human N-acetyltransferase-1 (NAT1) and -2 (NAT2).
Hein DW et al.
Current Protocols in Toxicology, 2005
[The association of NAT2 polymorphisms with sporadic breast cancer].
Artamonov VV et al.
Molekuliarnaia Biologiia, 0
[Identification of functionally significant mutations in NAT2 gene using biological microchips].
Kozhekbaeva ZhM et al.
Molekuliarnaia Biologiia, 0